Semaglutide clinical results

Semaglutide is a medication that belongs to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RAs). It is FDA-approved for type 2 diabetes (Ozempic®) and, at a higher dose, for chronic weight management (Wegovy®).

In clinical trials, semaglutide has demonstrated efficacy in promoting weight loss. However, like any medication, it can have potential side effects. Some common side effects of semaglutide include nausea, vomiting, diarrhea, and constipation. These side effects are usually mild and tend to improve over time as the body adjusts to the medication. In rare cases, more serious side effects such as pancreatitis or kidney problems have been reported, although the risk is generally considered low.

It’s important to note that semaglutide for weight management is typically prescribed at higher doses than for diabetes treatment, and the safety profile may differ between these uses. Research on long-term use for weight management is ongoing.

If you’re considering using semaglutide or any other medication, it’s crucial to consult with a healthcare professional who can evaluate your individual circumstances, assess the potential benefits and risks, and guide you through the decision-making process. They can provide you with the most up-to-date and personalized information based on your health history and needs.